Добірка наукової літератури з теми "GBV screening"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "GBV screening".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "GBV screening"
Watanabe, Maria Angelica Ehara, Ana Karina Melim Benthien Miquelão, Carlos Eduardo Coral de Oliveira, Karen Brajão de Oliveira, Thiago Franco Nasser, Mateus Nóbrega Aoki, Patrícia Sayuri Suzuki, Marla Karine Amarante, Emerson José Venâncio, and Elbens Marcos Minoreli de Azevedo. "Detection of GBV-C/HGV RNA in cervico-vaginal smears from healthy individuals." Brazilian Archives of Biology and Technology 51, no. 5 (October 2008): 917–22. http://dx.doi.org/10.1590/s1516-89132008000500007.
Повний текст джерелаBally, Cyrus Ashivira, Proscovia Adema, Kennedy Situma, Samuel Musau, Roberts Osangale, and Grace Kibet. "ENORMITY AND PATTERNS OF GENDER BASED VIOLENCE AT KENYA MEDICAL TRAINING COLLEGE CAMPUSES." International Journal of Health Sciences 5, no. 1 (July 19, 2022): 33–51. http://dx.doi.org/10.47941/ijhs.933.
Повний текст джерелаAryal, Shreyashi, Sagun B. Pant, and Sebina Baniya. "Gender-based Violence in Women attending Gynecology Outpatient Department in a Hospital of Western Nepal: An Issue of Endurance and Invisibility." Journal of South Asian Federation of Obstetrics and Gynaecology 9, no. 3 (August 2017): 225–29. http://dx.doi.org/10.5005/jp-journals-10006-1500.
Повний текст джерелаYalcinoz-Ucan, Busra, Laura Zilney, Agnes Zientarska-Kayko, Timothy Ireland, and Dillon Thomas Browne. "Examining the effectiveness of psychological interventions for marginalised and disadvantaged women and individuals who have experienced gender-based violence: protocol for a scoping review." BMJ Open 12, no. 7 (July 2022): e060479. http://dx.doi.org/10.1136/bmjopen-2021-060479.
Повний текст джерелаDecker, Michele R., Carrie Lyons, Kathleen Guan, Vanessa Mosenge, Ghislane Fouda, Daniel Levitt, Anna Abelson, et al. "A Systematic Review of Gender-Based Violence Prevention and Response Interventions for HIV Key Populations: Female Sex Workers, Men Who Have Sex With Men, and People Who Inject Drugs." Trauma, Violence, & Abuse 23, no. 2 (February 11, 2022): 676–94. http://dx.doi.org/10.1177/15248380211029405.
Повний текст джерелаKeys, Jessica R., Peter A. Leone, Joseph J. Eron, Kelcie Alexander, Myra Brinson, and Ronald Swanstrom. "Large scale screening of human sera for HCV RNA and GBV-C RNA." Journal of Medical Virology 86, no. 3 (October 31, 2013): 473–77. http://dx.doi.org/10.1002/jmv.23829.
Повний текст джерелаWijegunasekara, JLHR, and KDP Wijesinghe. "Health Sector Interventions to address Gender Based Violence: in Sri Lanka." Journal of Medical Research 6, no. 5 (October 28, 2020): 246–48. http://dx.doi.org/10.31254/jmr.2020.6515.
Повний текст джерелаValentine Chidi Obidile, Antor Odu Ndep, Onyeka Chukwudalu Ekwebene, Chidozie Precious Azubike, Lois Ezinne Obidile-Ikwegbu, Ray-Desmond Umechinedu, and Charles Nnamdi Ezeaka. "Post gender-based violence care, support services and health outcomes among victims of gender-based violence in Akwa Ibom and Cross-River States Nigeria." International Journal of Science and Research Archive 6, no. 2 (July 30, 2022): 006–15. http://dx.doi.org/10.30574/ijsra.2022.6.2.0138.
Повний текст джерелаNordbø, Svein Arne, Sidsel Krokstad, Per Winge, Finn Egil Skjeldestad, and Are B. Dalen. "Prevalence of GB Virus C (Also Called Hepatitis G Virus) Markers in Norwegian Blood Donors." Journal of Clinical Microbiology 38, no. 7 (2000): 2584–90. http://dx.doi.org/10.1128/jcm.38.7.2584-2590.2000.
Повний текст джерелаSchuler, Sidney Ruth, Quach Thu Trang, Vu Song Ha, and Hoang Tu Anh. "Qualitative Study of an Operations Research Project to Engage Abused Women, Health Providers, and Communities in Responding to Gender-Based Violence in Vietnam." Violence Against Women 17, no. 11 (November 2011): 1421–41. http://dx.doi.org/10.1177/1077801211433990.
Повний текст джерелаДисертації з теми "GBV screening"
Bergseng, Håkon. "Aspects of Group B streptococcus(GBS) disease in the newborn : Epidemiology, characterisation of invasive strains and evaluation of intrapartum screening." Doctoral thesis, Norges teknisk-naturvitenskapelige universitet, Institutt for laboratoriemedisin, barne- og kvinnesykdommer, 2009. http://urn.kb.se/resolve?urn=urn:nbn:no:ntnu:diva-5527.
Повний текст джерелаKilimann, Stephanie. "Pharmakogenetisches Screening bei Erstdiagnose einer Schizophrenie: Existiert hinsichtlich der Leistungserstattung ein gesundheitsökonomischer Nutzen seitens der GKV? - Entwicklung eines gesundheitsökonomischen Evaluationskonzepts." Master's thesis, Dresden International University, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133079.
Повний текст джерелаPurpose: Development of a health-economic investigation method to study whether a cost reduction under concurrent optimisation of the medical use exists by using pharmacogenetic a- priori- screening with first diagnosis of a schizophrenia. Final objective is the reimbursement of pharmacogenetic diagnostics for the indication schizophrenia in the German health statutory insurance (GKV). Methods: A prospective, randomised and controlled, 3-armed, parallel, open, multicentre pilot study with a duration of 3 years was designed based on the actual status of genetic-diagnostic research as well as the evidence-based therapy of schizophrenia. Study population: 300 patients (1:1:1) aged 18 to 65 years with initial F20 diagnosis (ICD-10). Interventions: pharmacogenetic screening and integrated care; integrated care; standard care. For evaluation of the medical benefit the clinical outcome is measured at defined times with regard to the patients' relevant endpoints mortality, morbidity, quality of life and side effects. In perspective relevant costs are determined by "piggy back" procedure. Results: In view of actually existing limitations within the German health system (e.g., insufficient intersectional medication and information management) the integrated care is considered being a suitable setting to demonstrate the advantage of using pharmacogenetic screening. Nevertheless, the integrated care does not show the general standard of the psychiatric patient's care at the moment. From GKV perspective essential cost drivers of schizophrenia therapy are relapses, hospital stays, unemployment and untimely superannuation. Diminishing the rate of these parametres could lead, e.g., to a reduction of the first year medical costs (at the moment approx. 30% of the total expenses). The cost-effectiveness analysis seems to be the study form with the slightest susceptibility to bias and confounding. In spite of a relatively high external validity the study setting is not unconditionally transferable to the German health system. Currently no general recommendation exists for the application of the genetic diagnostics to manage medication therapy in psychiatry. Up to now also the integrated care has not found a comprehensive entry in psychiatric practice, so that the described limitations are complicating a positive use proof. Nevertheless, the investigational concept can be regarded as feasible. Conclusion: Based on the existing situation the GKV's interest in performing a health-economic evaluation, which is focussed on the reimbursement of pharmacogenetic a priori-diagnostics in schizophrenia, is considered to be low. However, the situation may change in view of the expected update of the S3-practise guideline with the focus on structured and integrated care as well as the action plan „individualised medicine“ of the German federal research ministry. Thus, there is hope for changing interests in a pilot study. Based on care-related pilot studies as presented here, further research activities and practical testing of recent gene diagnostic procedures are necessary to demonstrate the relevance of the methodology for psychiatric practice
Dantas, Hebertty Vieira. "Triagem da qualidade de amostras de GNV e GLP usando espectrometria NIR e quimiometria." Universidade Federal da Paraíba, 2010. http://tede.biblioteca.ufpb.br:8080/handle/tede/7186.
Повний текст джерелаCoordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES
The search for new energy sources and concern about environmental problems has caused an increase in the use of gaseous fuels like natural gas (CNG) and liquefied petroleum gas (LPG). The main advantages of these fuels besides clean energy, are low production and processing costs, high efficiency and versatility. Given these realities, there is both growing need and demand for quality controls applicable to these types of fuel. This study proposes quality screening analysis of gaseous fuels using near infrared (NIR) absorption spectroscopy for verifying adulteration and/or nonconformity of LPG and CNG samples. The development of gas handling equipment made possible the construction of different classification models for screening analysis, such as SIMCA, SPA-SPA-LDA and SIMCA. To build and test these models, several samples were grouped as; tampered with, adulterated, and commercially certified standard. The results demonstrated the methodology as effective and robust for performing preliminary analysis of CNG and LPG quality, minimizing normal drawbacks of the quality control reference methods used for these fuels.
A busca por novas fontes de energia e a preocupação com problemas ambientais provocaram um aumento no uso de combustíveis gasosos como o gás natural veicular (GNV) e gás liquefeito de petróleo (GLP). Entre as principais vantagens desses combustíveis, destacam-se o baixo custo de produção e processamento, sua grande eficiência e versatilidade, além de ser uma fonte limpa de energia. Diante dessa realidade, cresce também a necessidade e a demanda pelo monitoramento da qualidade e fiscalização desse tipo de combustível. Esse trabalho propõe a utilização da análise de triagem da qualidade dos combustíveis gasosos por espectroscopia de absorção no infravermelho próximo (NIR) para verificação de adulterações ou nãoconformidades de amostras de GLP e GNV. O desenvolvimento de equipamentos de manipulação de gases possibilitou a construção de diferentes modelos de classificação para análise de triagem, tais como, SIMCA, SPA-LDA e o SPASIMCA. Para construir e testar esses modelos, foram agrupadas diversas amostras adulteradas, não-adulteradas e padrões certificados comercialmente. Os resultados demonstraram que a metodologia desenvolvida é bastante eficaz e robusta ao realizar análises preliminares da qualidade do GNV e GLP, minimizando alguns inconvenientes dos métodos de referência utilizados para o controle de qualidade desses combustíveis.
Dantas, Hebertty Vieira. "Um sistema em fluxo para preparação de misturas gasosas e análise screening de GNV e GLP com respeito ao conteúdo de metano e propano usando espectrometria NIR e quimiometria." Universidade Federal da Paraíba, 2014. http://tede.biblioteca.ufpb.br:8080/handle/tede/7147.
Повний текст джерелаCoordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES
Concern about environmental problems triggered the search for new sources of energy and consequently caused an increase in the use of gaseous fuels such as natural gas (NG) and liquefied petroleum gas (LPG). Given this reality, there is growing demand for quality monitoring and supervision of this type of fuel. This paper proposes a flow system for the screening of samples of LPG and NG by near infrared spectrometry (NIR) analysis in order to verify the quality of these fuels in relation to its major concentration of hydrocarbons, propane and methane, respectively. For this, one spectrophotometric flow cell for gas, seven NG containers collectors and one flow system for injection and mixture of gases, as well as its automation (SAIMG) and building management software (GasMixer) were developed. The gas handling equipment and systems for flow enabled the development of SPA-LDA and SIMCA models for screening analysis of samples of LPG and NG. The classification models were constructed and tested with commercial samples that have been previously grouped and analyzed by gas chromatography. Adulterated NG mixtures with nitrogen, compressed air, ethane and lighter fluid were also created. LPG samples were grouped into two different classes depending on the concentration of propane, which have been termed "rich LPG" and "poor LPG" The NG samples were analyzed according to the specified limit for the concentration of methane, which resulted in negative cases ( NG -) and positive (NG +) when they are considered respectively higher or lower than the limits set limit. The results showed that the screening analysis was efficient and robust, reaching 100% accuracy compared samples of LPG and NG test. In addition, the automation of the flow system optimizes all stages of the analysis and enhances their use in future applications
A preocupação com os problemas ambientais impulsionaram a busca por novas fontes de energia e consequentemente provocaram um aumento no uso de combustíveis gasosos como o gás natural veicular (GNV) e gás liquefeito de petróleo (GLP). Diante dessa realidade, cresce também a demanda pelo monitoramento da qualidade e fiscalização desse tipo de combustível. Esse trabalho propõe um sistema em fluxo para a análise screening de amostras de GLP e GNV através da espectrometria no infravermelho próximo (NIR), a fim de verificar a qualidade desses combustíveis em relação a concentração de seus hidrocarbonetos majoritários, o propano e o metano, respectivamente. Para tanto, foram desenvolvidos uma célula espectrofotométrica de fluxo para gás, sete recipientes coletores de GNV e um sistema em fluxo para introdução e mistura de gases, bem como sua automação (SAIMG) e criação de um software de gerenciamento (GasMixer). Os equipamentos de manipulação gasosa e o sistemas em fluxo possibilitaram o desenvolvimento dos modelos SIMCA e SPA-LDA para análise screening de amostras de GLP e GNV. Os modelos de classificação foram construidos e testados com amostras comerciais que foram agrupadas e analisadas previamente por cromatografia gasosa. Também foram criadas misturas adulteradas de GNV com nitrogênio, ar comprimido, etano e fluido de isqueiro. As amostras de GLP foram agrupadas em duas classes distintas em função da concentração de propano, as quais foram denominadas GLP rico e GLP pobre . As amostras de GNV foram analisadas de acordo com o limite especificado para a concentração de metano, o que resultou em casos negativos (GNV !) e positivos (GNV +) quando são considerados respectivamente superiores ou inferiores aos limites estabelecidos. Os resultados demonstraram que a análise screening foi eficaz e robusta, alcançando 100% de acerto em relação as amostras de teste de GLP e GNV. Além disso, a automação do sistema em fluxo otimiza todas as etapas da análise e potencializa seu uso em aplicações futuras.
Bray, B. A., I. C. Sutcliffe, and Dean J. Harrington. "Impact of lgt mutation on lipoprotein biosynthesis and in vitro phenotypes of Streptococcus agalactiae." 2009. http://hdl.handle.net/10454/11570.
Повний текст джерелаAlthough Streptococcus agalactiae, the group B Streptococcus, is a leading cause of invasive neonatal disease worldwide the molecular basis of its virulence is still poorly understood. To investigate the role of lipoproteins in the physiology and interaction of this pathogen with host cells, we generated a mutant S. agalactiae strain (A909DeltaLgt) deficient in the Lgt enzyme and thus unable to lipidate lipoprotein precursors (pro-lipoproteins). The loss of pro-lipoprotein lipidation did not affect the viability of S. agalactiae or its growth in several different media, including cation-depleted media. The processing of two well-characterized lipoproteins, but not a non-lipoprotein, was clearly shown to be aberrant in A909DeltaLgt. The mutant strain was shown to be more sensitive to oxidative stress in vitro although the molecular basis of this increased sensitivity was not apparent. The inactivation of Lgt also resulted in changes to the bacterial cell envelope, as demonstrated by reduced retention of both the group B carbohydrate and the polysaccharide capsule and a statistically significant reduction (P=0.0079) in A909DeltaLgt adherence to human endothelial cells of fetal origin. These data confirm that failure to process lipoproteins correctly has pleiotropic effects that may be of significance to S. agalactiae colonization and pathogenesis.
Kilimann, Stephanie. "Pharmakogenetisches Screening bei Erstdiagnose einer Schizophrenie: Existiert hinsichtlich der Leistungserstattung ein gesundheitsökonomischer Nutzen seitens der GKV? - Entwicklung eines gesundheitsökonomischen Evaluationskonzepts." Master's thesis, 2013. https://diu.qucosa.de/id/qucosa%3A21569.
Повний текст джерелаPurpose: Development of a health-economic investigation method to study whether a cost reduction under concurrent optimisation of the medical use exists by using pharmacogenetic a- priori- screening with first diagnosis of a schizophrenia. Final objective is the reimbursement of pharmacogenetic diagnostics for the indication schizophrenia in the German health statutory insurance (GKV). Methods: A prospective, randomised and controlled, 3-armed, parallel, open, multicentre pilot study with a duration of 3 years was designed based on the actual status of genetic-diagnostic research as well as the evidence-based therapy of schizophrenia. Study population: 300 patients (1:1:1) aged 18 to 65 years with initial F20 diagnosis (ICD-10). Interventions: pharmacogenetic screening and integrated care; integrated care; standard care. For evaluation of the medical benefit the clinical outcome is measured at defined times with regard to the patients' relevant endpoints mortality, morbidity, quality of life and side effects. In perspective relevant costs are determined by "piggy back" procedure. Results: In view of actually existing limitations within the German health system (e.g., insufficient intersectional medication and information management) the integrated care is considered being a suitable setting to demonstrate the advantage of using pharmacogenetic screening. Nevertheless, the integrated care does not show the general standard of the psychiatric patient's care at the moment. From GKV perspective essential cost drivers of schizophrenia therapy are relapses, hospital stays, unemployment and untimely superannuation. Diminishing the rate of these parametres could lead, e.g., to a reduction of the first year medical costs (at the moment approx. 30% of the total expenses). The cost-effectiveness analysis seems to be the study form with the slightest susceptibility to bias and confounding. In spite of a relatively high external validity the study setting is not unconditionally transferable to the German health system. Currently no general recommendation exists for the application of the genetic diagnostics to manage medication therapy in psychiatry. Up to now also the integrated care has not found a comprehensive entry in psychiatric practice, so that the described limitations are complicating a positive use proof. Nevertheless, the investigational concept can be regarded as feasible. Conclusion: Based on the existing situation the GKV's interest in performing a health-economic evaluation, which is focussed on the reimbursement of pharmacogenetic a priori-diagnostics in schizophrenia, is considered to be low. However, the situation may change in view of the expected update of the S3-practise guideline with the focus on structured and integrated care as well as the action plan „individualised medicine“ of the German federal research ministry. Thus, there is hope for changing interests in a pilot study. Based on care-related pilot studies as presented here, further research activities and practical testing of recent gene diagnostic procedures are necessary to demonstrate the relevance of the methodology for psychiatric practice.
Книги з теми "GBV screening"
Waldek, Stephen. Fabry disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0338_update_001.
Повний текст джерелаЧастини книг з теми "GBV screening"
Olibet, Ylenia, and Alanna Thain. "Vidéo de Femmes Dans le Parc: Feminist Rhythms and Festival Times Under Covid." In Rethinking Film Festivals in the Pandemic Era and After, 155–75. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-14171-3_8.
Повний текст джерелаDecker, Michele R., Elizabeth Miller, and Nancy Glass. "Gender-based Violence Assessment in the Health Sector and Beyond." In Preventing Intimate Partner Violence. Policy Press, 2017. http://dx.doi.org/10.1332/policypress/9781447333050.003.0005.
Повний текст джерелаBaldwin, Andrew, Nina Hjelde, Charlotte Goumalatsou, and Gil Myers. "Obstetrics." In Oxford Handbook of Clinical Specialties, 1–97. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198719021.003.0001.
Повний текст джерелаТези доповідей конференцій з теми "GBV screening"
Ma, Liang, Jeremy Barker, Changchun Zhou, Biaoyang Lin, and Wei Li. "A Perfused Two-Chamber System for Anticancer Drug Screening." In ASME 2010 International Manufacturing Science and Engineering Conference. ASMEDC, 2010. http://dx.doi.org/10.1115/msec2010-34326.
Повний текст джерелаCiarrocchi, Alberto, Wei Quan, Markus Blaser, Maria Hämmerli, and Hektor Meier. "Optical Damage Threshold Screening Methodology for 28 GBd, Long Wavelength Avalanche Photodiodes." In Optical Fiber Communication Conference. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/ofc.2022.th2a.39.
Повний текст джерелаCiarrocchi, Alberto, Wei Quan, Markus Blaser, Maria Hämmerli, and Hektor Meier. "Optical Damage Threshold Screening Methodology for 28 GBd, Long Wavelength Avalanche Photodiodes." In Optical Fiber Communication Conference. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/ofc.2022.th2a.39.
Повний текст джерелаSeedat, F., J. Geppert, C. Stinton, J. Patterson, CS Brown, B. Tan, K. Freeman, et al. "OP34 Universal antenatal culture-based screening for maternal group b streptococcus (gbs) carriage to prevent early-onset gbs disease: a systematic review for the uk national screening committee (nsc)." In Society for Social Medicine, 61st Annual Scientific Meeting, University of Manchester, 5–8 September 2017. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/jech-2017-ssmabstracts.34.
Повний текст джерелаNwosu, Jazzpin-Cross Chiemerie. "Carbon Capture, Utilisation & Storage in Offshore Facilities." In ADIPEC. SPE, 2022. http://dx.doi.org/10.2118/210805-ms.
Повний текст джерелаMa, Liang, Lei Gao, Yichen Luo, Huayong Yang, Bin Zhang, Changchun Zhou, JinGyu Ock, and Wei Li. "Flow Analysis of a Porous Polymer-Based Three-Dimensional Cell Culture Device for Drug Screening." In ASME 2018 13th International Manufacturing Science and Engineering Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/msec2018-6313.
Повний текст джерелаHorenkamp-Sonntag, D., EM Bitzer, and S. Geyer. "Gebärmutterhalskrebs-Früherkennung: Veränderung der jährlichen Screening-Inanspruchnahme im (Lang-) Zeitverlauf auf Basis von GKV-Routinedaten." In „Neue Ideen für mehr Gesundheit“. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1694644.
Повний текст джерелаHorenkamp-Sonntag, D., EM Bitzer, and S. Geyer. "Behandlungsfade in GKV-Routinedaten: Status-Quo der Screening-Inanspruchnahme beim Gebärmutterhalskrebs vor Einführung des HPV-Tests." In Das Soziale in Medizin und Gesellschaft – Aktuelle Megatrends fordern uns heraus 56. Jahrestagung der Deutschen Gesellschaft für Sozialmedizin und Prävention (DGSMP). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1732721.
Повний текст джерелаBarreto, Catharina Mello, Amanda Ferraz Arita, Ana Carolina Coutinho Engelhardt Bravin, Julia Surrage da Matta, Maria de Fatima Araujo da Fonseca, and Pietra Sardinha Silvestre Mousinho. "Epidemiological analysis of strokes in Grande Vitória, Espírito Santo." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.207.
Повний текст джерелаChang, Cindy, Jack Stapleton, Donna Klinzman, Lars Larson, Hormuzd Katki, Mark Purdue, and Eric A. Engels. "Abstract 2538: GB virus C viremia and subsequent risk of non-Hodgkin lymphoma in the PLCO screening trial." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2538.
Повний текст джерелаЗвіти організацій з теми "GBV screening"
Haley, Mark V., Roman G. Kuperman, and Ronald T. Checkai. Aquatic Toxicity Screening of an ACWA Secondary Waste, GB-Hydrolysate. Fort Belvoir, VA: Defense Technical Information Center, January 2009. http://dx.doi.org/10.21236/ada494193.
Повний текст джерелаFridman, Eyal, Jianming Yu, and Rivka Elbaum. Combining diversity within Sorghum bicolor for genomic and fine mapping of intra-allelic interactions underlying heterosis. United States Department of Agriculture, January 2012. http://dx.doi.org/10.32747/2012.7597925.bard.
Повний текст джерела